Central nervous system analgesics

AfaSci has developed small New Chemical Entities (NCEs) that differentially inhibit ion channels and exhibit state-dependent modulation of neuronal activity. The lead compounds produce in vivo efficacy against epilepsy and nerve injury-induced neuropathic pain, diabetes- or chemotherapy-induced peripheral neuropathy in rodents.

Status: IND enabling studies ongoing